Covered recipient · General Payments record
MEREDITH ANN MCKEAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$34,451.12
106 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $18,966.60 | 16 |
| Consulting Fee | $11,635.00 | 3 |
| Food and Beverage | $3,219.52 | 86 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $630.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MEREDITH ANN MCKEAN
NPI 1437425659 · CMS profile ID 2767983
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NASHVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MEREDITH ANN MCKEAN, NPI 1437425659, CMS profile ID 2767983, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437425659?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
106 matching records · $34,451.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 106.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.18 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963418 | CMS |
| Merck Sharp & Dohme LLC | $29.41 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141903378 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $15.84 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086115548 | CMS |
| Eisai Inc. | $22.39 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110765297 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.08 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101736820 | CMS |
| Iovance Biotherapeutics, Inc. | $22.33 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147113416 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8.47 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114112101 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,875.00 | 08/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101736810 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.16 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105252373 | CMS |
| Daiichi Sankyo Inc. | $22.34 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089455176 | CMS |
| Kyowa Kirin, Inc. | $16.36 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127037422 | CMS |
| Regeneron Healthcare Solutions, Inc. | $90.17 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114112099 | CMS |
| Exelixis Inc. | $14.83 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138561874 | CMS |
| Merck Sharp & Dohme LLC | $31.98 | 06/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141947643 | CMS |
| Daiichi Sankyo Inc. | $29.56 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089455174 | CMS |
| Genentech USA, Inc. | $17.74 | 06/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068743 | CMS |
| Incyte Corporation | $21.90 | 06/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141311471 | CMS |
| Celgene Corporation | $18.87 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101179642 | CMS |
| Novartis Pharmaceuticals Corporation | $28.46 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963416 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101736784 | CMS |
| Janssen Biotech, Inc. | $20.72 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078671234 | CMS |
| PFIZER INC. | $150.00 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131461785 | CMS |
| Delcath Systems | $118.06 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130859330 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8.71 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114112097 | CMS |
| ARRAY BIOPHARMA INC | $630.00 | 05/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131597486 | CMS |
| Genmab U.S., Inc. | $21.46 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126829704 | CMS |
| Immunocore Limited | $125.20 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103097207 | CMS |
| Merck Sharp & Dohme LLC | $31.37 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141801360 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17.83 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152182083 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.87 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105544727 | CMS |
| F. Hoffmann-La Roche AG | $845.34 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068747 | CMS |
| F. Hoffmann-La Roche AG | $155.62 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068751 | CMS |
| F. Hoffmann-La Roche AG | $279.46 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068755 | CMS |
| F. Hoffmann-La Roche AG | $9,423.61 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068759 | CMS |
| F. Hoffmann-La Roche AG | $103.54 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133068763 | CMS |
| Daiichi Sankyo Inc. | $28.48 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089455172 | CMS |
| Immunocore Limited | $122.27 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103097125 | CMS |
| Daiichi Sankyo Inc. | $17.61 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089455170 | CMS |
| Verity Pharmaceuticals Inc. | $21.32 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080605918 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.52 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093890903 | CMS |
| Deciphera Pharmaceuticals Inc. | $22.34 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145874159 | CMS |
| Lilly USA, LLC | $31.78 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135171502 | CMS |
| Novartis Pharmaceuticals Corporation | $31.88 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963414 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.05 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114112095 | CMS |
| Delcath Systems | $154.00 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130859728 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.44 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105429615 | CMS |
| Daiichi Sankyo Inc. | $2,055.00 | 02/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089455164 | CMS |
| Merck Sharp & Dohme LLC | $24.03 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141903376 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.34 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105759343 | CMS |
| Gilead Sciences, Inc. | $22.86 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133841916 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,210.81 | 9 |
| PY2025 | Principal investigator | $2,968,025.66 | 971 |
| PY2024 | Recipient | $10,299.19 | 10 |
| PY2024 | Principal investigator | $2,203,641.66 | 817 |
| PY2023 | Recipient | $12,628.46 | 43 |
| PY2023 | Principal investigator | $2,492,754.75 | 523 |
| PY2022 | Recipient | $5,501.69 | 17 |
| PY2022 | Principal investigator | $4,173,649.03 | 571 |
| PY2021 | Recipient | $6,391.30 | 7 |
| PY2021 | Principal investigator | $2,633,751.67 | 317 |
| PY2020 | Principal investigator | $1,227,757.68 | 85 |
| PY2019 | Principal investigator | $202,429.12 | 29 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
980 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 12/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304833 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 12/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304835 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152 | No dispute reported | 06/30/2026 | 1249019566 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,426.30 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498613 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,596.05 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184279354 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184279390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,700.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184279442 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,977.80 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043444 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,546.45 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043446 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $375.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043448 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 12/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043450 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 12/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816968 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,542.75 | 12/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304829 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,206.25 | 12/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304831 |
| Principal investigator 1 | ModernaTX, Inc. | $850.00 | 12/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968633 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228745712 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,320.00 | 12/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276244 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 12/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184276254 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $9,210.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498517 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $7,000.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498605 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498631 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,850.00 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498669 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 12/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,863.00 | 12/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274803 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $36,667.35 | 12/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043442 |
| Principal investigator 1 | Genentech, Inc. | $562.50 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649955 |
| Principal investigator 1 | Genentech, Inc. | $1,095.75 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649960 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184268697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184268699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184268701 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 12/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081787 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 12/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655734 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,200.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184267301 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,444.55 | 11/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304777 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,461.40 | 11/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304779 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,228.90 | 11/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 11/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184265917 |
| Principal investigator 1 | PFIZER INC. | $6,693.30 | 11/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228728123 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,723.95 | 11/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184264375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,119.50 | 11/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184264381 |
| Principal investigator 1 | PFIZER INC. | $1,450.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228728409 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,106.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184263359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 11/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184263361 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968631 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968657 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,542.75 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304767 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,263.30 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304769 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,596.05 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304771 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304773 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304775 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,206.25 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304781 |
| Principal investigator 1 | Ipsen Pharma SAS | $116.10 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304785 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043440 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228730130 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 11/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968629 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081791 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081800 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081805 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $137.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081809 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $56.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081814 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $102.02 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081822 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081826 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081830 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081832 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081835 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081839 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081844 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081847 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081851 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081856 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081881 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081885 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081889 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081892 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081896 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081899 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081903 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $125.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081907 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081911 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081915 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $125.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081919 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $60.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082026 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082030 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $60.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082038 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082043 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082047 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $137.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082051 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082056 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $56.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082059 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $125.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082064 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $102.02 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082068 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $137.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082072 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082076 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $56.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082080 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082082 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $102.02 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082084 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082087 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082091 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082095 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082098 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082103 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082106 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082110 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082114 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082119 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082122 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082127 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082132 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082136 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082140 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082144 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082148 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082152 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $137.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082156 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082160 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $56.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082164 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082169 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $102.02 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082173 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082177 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082180 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082184 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082188 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082193 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082197 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082201 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082209 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082217 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082229 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082237 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71.25 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082245 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082254 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $112.20 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082261 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082271 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082283 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $137.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082292 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082305 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $43.75 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082317 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082329 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37.50 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082341 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 11/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226082350 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228737581 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152 | No dispute reported | 06/30/2026 | 1249019564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382864 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184257771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184257773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,700.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184258045 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043436 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.73 | 11/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043438 |
| Principal investigator 1 | PFIZER INC. | $11,510.00 | 11/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228724384 |
| Principal investigator 1 | PFIZER INC. | $48,789.50 | 11/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228737745 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498615 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498617 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498619 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498633 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498635 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498637 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,400.00 | 11/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655732 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,196.15 | 10/31/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304751 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,706.45 | 10/31/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304753 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252498629 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252498649 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252498661 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252498667 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304749 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 10/29/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304755 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,863.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,550.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184253893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,700.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184253895 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,358.20 | 10/29/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043434 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816964 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,781.40 | 10/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043432 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $9,050.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252498627 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,187.80 | 10/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382856 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382880 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382884 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 10/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382890 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,349.00 | 10/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184249122 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,260.65 | 10/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043427 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649895 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $20,341.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498469 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228723538 |
| Principal investigator 1 | PFIZER INC. | $4,325.00 | 10/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228730529 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $15,000.00 | 10/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498609 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,000.00 | 10/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498611 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,850.00 | 10/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498653 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,850.00 | 10/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498663 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,383.15 | 10/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043425 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 10/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816960 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,075.00 | 10/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 10/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655730 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,750.00 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498621 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,750.00 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252498651 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649832 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 09/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019624 |
| Principal investigator 1 | BioNTech SE | $2,135.00 | 09/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019634 |
| Principal investigator 1 | BioNTech SE | $40.00 | 09/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019638 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,094.35 | 09/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,626.11 | 09/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,011.60 | 09/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382620 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 09/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304727 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184240282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184240284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184240286 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184240288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184240290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,723.95 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240756 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,092.50 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184240758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,000.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,000.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184240768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,400.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,420.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184240788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184240790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,700.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 | No dispute reported | 06/30/2026 | 1184240794 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,323.45 | 09/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043417 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,772.60 | 09/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043419 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 09/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382586 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382588 |
| Principal investigator 1 | PFIZER INC. | $2,700.00 | 09/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228752938 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE SGNCEACAM5C IN ADULTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228757757 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228757914 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649828 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,900.00 | 09/11/2025 | Non-covered Recipient Entity TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1190310162 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968635 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968643 |
| Principal investigator 1 | PFIZER INC. | $6,000.00 | 09/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228759617 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $258.14 | 09/10/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120197 |
| Principal investigator 1 | PFIZER INC. | $16,242.60 | 09/09/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228714132 |
| Principal investigator 1 | PFIZER INC. | $16,242.60 | 09/09/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville Sarah Cannon Research Inst Pharmacy | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228719243 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968647 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 09/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019695 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $17,859.15 | 09/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 09/03/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383556 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968649 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968655 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 09/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228760428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184233434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184233436 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $83,025.68 | 08/31/2025 | Non-covered Recipient Entity SCRI Oncology Partners | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 | No dispute reported | 06/30/2026 | 1232933500 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $104.73 | 08/29/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120195 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816958 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304689 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304699 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304701 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,000.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304703 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,500.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304705 |
| Principal investigator 1 | PFIZER INC. | $21,990.00 | 08/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228722992 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,834.65 | 08/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184230511 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968639 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,260.65 | 08/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382582 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382592 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382596 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382598 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382600 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382604 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382608 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382612 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382826 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,741.20 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228485 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,772.60 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043409 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043411 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,772.60 | 08/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043500 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,300.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304687 |
| Principal investigator 1 | Ipsen Pharma SAS | $15,000.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304691 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,000.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304693 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,500.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304697 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,300.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304707 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,300.00 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304709 |
| Principal investigator 1 | BioNTech SE | $747.00 | 08/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382590 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382594 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41,536.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36,344.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36,344.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,278.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,900.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382818 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $131,800.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497679 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $8,550.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497883 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,500.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497885 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,850.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497887 |
| Principal investigator 1 | Ipsen Pharma SAS | $500.00 | 08/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184223066 |
| Principal investigator 1 | BioNTech SE | $2,057.40 | 07/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,439.06 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,125.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382802 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968653 |
| Principal investigator 1 | PFIZER INC. | $1,081.35 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228783418 |
| Principal investigator 1 | PFIZER INC. | $8,010.00 | 07/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228790578 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 07/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228763153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382578 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382622 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382624 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382632 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $432.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382634 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382636 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382638 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382642 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382644 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $432.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $432.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382650 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382652 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382654 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382658 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382660 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382662 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382666 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382668 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382670 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382674 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382678 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382680 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382684 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382686 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382690 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382692 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382696 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382700 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382706 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382722 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382740 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382840 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649824 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,525.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497897 |
| Principal investigator 1 | PFIZER INC. | $3,248.52 | 07/21/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228714134 |
| Principal investigator 1 | PFIZER INC. | $3,248.52 | 07/21/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville Sarah Cannon Research Inst Pharmacy | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228719246 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228720489 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649834 |
| Principal investigator 1 | BioNTech SE | $39,432.60 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 07/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184214894 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,200.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 133421 | No dispute reported | 06/30/2026 | 1252497881 |
| Principal investigator 1 | BioNTech SE | $40.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019636 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,000.00 | 07/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043407 |
| Principal investigator 1 | BioNTech SE | $3,466.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019630 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184213071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184213073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184213081 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,750.00 | 07/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043403 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 07/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655724 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 07/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228723560 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $850.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816956 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,800.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184212231 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816954 |
| Principal investigator 1 | Epizyme, Inc. | $48,879.50 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184281964 |
| Principal investigator 1 | Epizyme, Inc. | $7,974.75 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184281966 |
| Principal investigator 1 | PFIZER INC. | $1,737.45 | 06/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228777189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $523.55 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.55 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $899.10 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382556 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 06/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382566 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $10,500.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496213 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $996.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496215 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,900.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496217 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496221 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,000.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496223 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $15,000.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496225 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 06/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496229 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228791731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $89.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382450 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 06/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184209916 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 06/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184209918 |
| Principal investigator 1 | BioNTech SE | $2,621.70 | 06/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 06/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184209322 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 06/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184209324 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 06/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043397 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 06/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043399 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15,000.00 | 06/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1244043401 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $500.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184207189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184207191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,825.20 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184207235 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $177,799.73 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081985 |
| Principal investigator 1 | PFIZER INC. | $8,010.00 | 06/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228791415 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 06/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019614 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,000.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | 117145 | No dispute reported | 06/30/2026 | 1252496227 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $119.77 | 06/06/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120193 |
| Principal investigator 1 | BioNTech SE | $457.20 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,500.00 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184204415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,000.00 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184204417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184204419 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968641 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968645 |
| Principal investigator 1 | Genentech, Inc. | $1,390.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1211651139 |
| Principal investigator 1 | PFIZER INC. | $2,525.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228786581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655722 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,500.00 | 06/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816950 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 06/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816952 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649796 |
| Principal investigator 1 | BioNTech SE | $2,941.20 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019588 |
| Principal investigator 1 | Epizyme, Inc. | $588.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184281968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184199065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,042.20 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,737.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199615 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199617 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,825.20 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199619 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199623 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199625 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,825.20 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184199633 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 05/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/27/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382548 |
| Principal investigator 1 | PFIZER INC. | $753.00 | 05/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228765064 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 05/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228773541 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,180.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382558 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649806 |
| Principal investigator 1 | PFIZER INC. | $6,363.90 | 05/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228774241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 05/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184197767 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382408 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,572.75 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382432 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,180.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382438 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382560 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382572 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/19/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382502 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649802 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649811 |
| Principal investigator 1 | BioNTech SE | $3,245.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019360 |
| Principal investigator 1 | BioNTech SE | $590.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019362 |
| Principal investigator 1 | BioNTech SE | $2,185.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019364 |
| Principal investigator 1 | BioNTech SE | $1,250.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019366 |
| Principal investigator 1 | BioNTech SE | $960.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019368 |
| Principal investigator 1 | BioNTech SE | $390.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019370 |
| Principal investigator 1 | BioNTech SE | $1,345.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019372 |
| Principal investigator 1 | BioNTech SE | $1,525.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019374 |
| Principal investigator 1 | BioNTech SE | $6,695.00 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019376 |
| Principal investigator 1 | BioNTech SE | $29,794.28 | 05/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019378 |
| Principal investigator 1 | Ipsen Pharma SAS | $147.00 | 05/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304633 |
| Principal investigator 1 | PFIZER INC. | $900.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228764693 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 05/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,180.00 | 05/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382378 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 05/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382380 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 05/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382382 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816946 |
| Principal investigator 1 | Ipsen Pharma SAS | $24.50 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304635 |
| Principal investigator 1 | BioNTech SE | $1,540.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019380 |
| Principal investigator 1 | BioNTech SE | $1,990.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019382 |
| Principal investigator 1 | BioNTech SE | $180.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT151-01 | No dispute reported | 06/30/2026 | 1249019384 |
| Principal investigator 1 | BioNTech SE | $2,621.70 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019408 |
| Principal investigator 1 | BioNTech SE | $588.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019598 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019604 |
| Principal investigator 1 | BioNTech SE | $2,621.70 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184193405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184193407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184193409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184193411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184193413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655720 |
| Principal investigator 1 | Ipsen Pharma SAS | $60.00 | 05/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304729 |
| Principal investigator 1 | Ipsen Pharma SAS | $70.00 | 05/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184191271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184191273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184191275 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $292.81 | 04/29/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120191 |
| Principal investigator 1 | PFIZER INC. | $18,612.45 | 04/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228780561 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,554.11 | 04/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226081982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382478 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382480 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382482 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,377.00 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382484 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,572.75 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382486 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382490 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,572.75 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382492 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,377.00 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382496 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,572.75 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382498 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,377.00 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382562 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382574 |
| Principal investigator 1 | Ipsen Pharma SAS | $73.07 | 04/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304619 |
| Principal investigator 1 | Ipsen Pharma SAS | $72.40 | 04/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304621 |
| Principal investigator 1 | Ipsen Pharma SAS | $69.28 | 04/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304627 |
| Principal investigator 1 | Ipsen Pharma SAS | $639.01 | 04/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304629 |
| Principal investigator 1 | Ipsen Pharma SAS | $85.99 | 04/18/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304631 |
| Principal investigator 1 | PFIZER INC. | $4,211.25 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228780467 |
| Principal investigator 1 | PFIZER INC. | $2,946.28 | 04/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT | No dispute reported | 06/30/2026 | 1228798598 |
| Principal investigator 1 | BioNTech SE | $3,169.80 | 04/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019584 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184183372 |
| Principal investigator 1 | PFIZER INC. | $596.00 | 04/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228779469 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 04/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228796483 |
| Principal investigator 1 | PFIZER INC. | $7,764.00 | 04/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228779014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184182000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184182002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184181894 |
| Principal investigator 1 | PFIZER INC. | $5,290.65 | 04/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228780939 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $396.99 | 04/05/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120189 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $396.52 | 04/03/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382374 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382386 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382388 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382396 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382400 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382402 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382404 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382406 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382440 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $773.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382442 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,572.75 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382444 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382446 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,377.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382448 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382452 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382454 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382456 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382458 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382460 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382462 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382464 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382466 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382468 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382472 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382568 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655718 |
| Principal investigator 1 | Epizyme, Inc. | $70.00 | 04/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184283095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184180516 |
| Principal investigator 1 | PFIZER INC. | $32,485.20 | 03/31/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228761498 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 03/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228724452 |
| Principal investigator 1 | PFIZER INC. | $22,115.00 | 03/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228797783 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $1,031.05 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946821 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 03/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816944 |
| Principal investigator 1 | Epizyme, Inc. | $1,100.00 | 03/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | No dispute reported | 06/30/2026 | 1184283011 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 03/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228783895 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 03/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228787999 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 03/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228780534 |
| Principal investigator 1 | PFIZER INC. | $4,692.60 | 03/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228787668 |
| Principal investigator 1 | BioNTech SE | $60,516.90 | 03/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 03/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184174352 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 03/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184174354 |
| Principal investigator 1 | Genentech, Inc. | $3,199.50 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649572 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649558 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184172612 |
| Principal investigator 1 | BioNTech SE | $40.00 | 03/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019735 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 03/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019737 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,189.64 | 03/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1226084831 |
| Principal investigator 1 | Epizyme, Inc. | $732.00 | 03/10/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184281954 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 03/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228779905 |
| Principal investigator 1 | PFIZER INC. | $12,601.24 | 03/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228797065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 03/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383072 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 03/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1211650310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655714 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 03/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816942 |
| Principal investigator 1 | Epizyme, Inc. | $70.00 | 03/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184283019 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $279.84 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995520 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995522 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $219.00 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995524 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10.80 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995526 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $4.23 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995528 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.28 | 02/25/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | DLL3CD3 phIb in glioma for PoCP | No dispute reported | 06/30/2026 | 1220995530 |
| Principal investigator 1 | PFIZER INC. | $4,692.60 | 02/25/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228758867 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $148.22 | 02/25/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120185 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,230.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382894 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,180.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,426.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,230.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,863.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,426.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,596.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,230.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,426.00 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,544.93 | 02/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383068 |
| Principal investigator 1 | PFIZER INC. | $16,242.60 | 02/24/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228760220 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184155118 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184154680 |
| Principal investigator 1 | PFIZER INC. | $23,551.77 | 02/18/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228769083 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $254.71 | 02/14/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120181 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $238.92 | 02/14/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | No dispute reported | 06/30/2026 | 1184120183 |
| Principal investigator 1 | Aadi Bioscience, Inc. | $3,000.00 | 02/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | No dispute reported | 06/30/2026 | 1181946819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,915.00 | 02/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1184153116 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,733.00 | 02/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1184153120 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,913.00 | 02/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1184153124 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019731 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649562 |
| Principal investigator 1 | PFIZER INC. | $59,667.37 | 02/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228760134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383140 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383152 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22.55 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383172 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383178 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383182 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383248 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.20 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 02/04/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,124.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,656.45 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223382998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,061.80 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,224.45 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $899.10 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $899.10 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,377.00 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,568.05 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,664.55 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.40 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,883.95 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,812.40 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,994.30 | 02/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | U31402-277 | No dispute reported | 06/30/2026 | 1223383066 |
| Principal investigator 1 | PFIZER INC. | $2,525.00 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228724648 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,811.70 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184151597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,034.00 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184151599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,811.70 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184151601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,706.30 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184151603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,340.10 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184151605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655712 |
| Principal investigator 1 | Epizyme, Inc. | $70.00 | 02/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184283017 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300.00 | 01/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816938 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 01/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816940 |
| Principal investigator 1 | PFIZER INC. | $19,400.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228801146 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649566 |
| Principal investigator 1 | Genentech, Inc. | $1,740.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211649569 |
| Principal investigator 1 | PFIZER INC. | $24,363.90 | 01/21/2025 | Non-covered Recipient Entity Tennessee Oncology Nashville | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228761492 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,200.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190303739 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,850.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1190304413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184148269 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1211650387 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $57.44 | 01/15/2025 | Non-covered Recipient Entity TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1190310164 |
| Principal investigator 1 | PFIZER INC. | $21,500.00 | 01/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228800602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184147553 |
| Principal investigator 1 | BioNTech SE | $1,850.00 | 01/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT152-01C | No dispute reported | 06/30/2026 | 1249019727 |
| Principal investigator 1 | Epizyme, Inc. | $8,380.02 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184281952 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252968651 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,040.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1190304479 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,685.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer | No dispute reported | 06/30/2026 | 1190304435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184146064 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220816936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.60 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.00 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $39.00 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.10 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $67.65 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.75 | 01/02/2025 | Non-covered Recipient Entity SCRI Oncology Partners | U31402-277 | No dispute reported | 06/30/2026 | 1223383252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Tennessee Oncology Ste 200 | A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 | No dispute reported | 06/30/2026 | 1220655716 |
| Principal investigator 1 | Epizyme, Inc. | $70.00 | 01/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1184283015 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $140.00 | 01/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer | No dispute reported | 06/30/2026 | 1190306509 |